Modeling and synthesis of non-cyclic derivatives of GPI-1046 as potential FKBP ligands with neurotrophic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4385-4390

  Zhao, Liqin ^a   Liu, Hongying ^a   Wang, Lili ^a   Li, Song ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Computer modeling; Dorsal root ganglion; FK506 binding protein; GPI 1046; Nerve growth factor; Neurotrophic activity; Synthesis

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; DRUG DERIVATIVE; FK 506 BINDING PROTEIN; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SYNTHESIS; NERVE GROWTH; NEURITE; NONHUMAN; SPINAL GANGLION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHICK EMBRYO; DRUG DESIGN; HUMANS; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; NEURONS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PYRROLIDINES; STREPTOMYCES; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 33745699198     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.044     Document Type: Article

References (20)

1. Lyons W.E., George E.B., Dawson T.M., Steiner J.P., and Snyder S.H. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3191
2. Sharkey J., and Butcher S.P. Nature 371 (1994) 336
3. Schreiber S.L. Science 251 (1991) 283
4. Gold B.G. Expert Opin. Invest. Drugs 9 (2000) 2331
5. Hamilton G.S., and Steiner J.P. J. Med. Chem. 41 (1998) 5119
6. Zhao L., Xiao J., Huang W., and Li S. Acta Pharm. Sin. 37 (2002) 743
7. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Nature 380 (1996) 252
8. McMahon S.B., and Priestley J.V. Curr. Opin. Neurobiol. 5 (1995) 616
9. Bierer B.E., Somers P.K., Wandless T.J., Burakoff S.J., and Schreiber S.L. Science 250 (1990) 556
10. Liu J., Farmer Jr. J.D., Lane W.S., Friedman J., Weissman I., and Schreiber S.L. Cell 66 (1991) 807
11. Kissinger C.R., Parge H.E., Knighton D.R., Lewis C.T., Pelletier L.A., Tempczyk A., Kalish V.J., Tucker K.D., Showalter R.E., and Moomaw E.W. Nature 378 (1995) 641
12. Steiner J.P., Connolly M.A., Valentine H.L., Hamilton G.S., Dawson T.M., Hester L., and Snyder S.H. Nat. Med. 3 (1997) 421
13. Khan Z., Ferrari G., Kasper M., Tonge D.A., Steiner J.P., Hamilton G.S., and Gordon-Weeks P.R. Neuroscience 114 (2002) 601
14. Li F., Omori N., Hayashi T., Jin G., Sato K., Nagano I., Shoji M., and Abe K. J. Neurosci. Res. 76 (2004) 383
15. Edlich F., Weiwad M., Wildemann D., Jarczowski F., Kilka S., Moutty M.C., Jahreis G., Lucke C., Schmidt W., Striggow F., and Fischer G. J. Biol. Chem. 281 (2006) 14961
16. Gold B.G. Drug Metab. Rev. 31 (1999) 649
17. Sich C., Improta S., Cowley D.J., Guenet C., Merly J.P., Teufel M., and Saudek V. Eur. J. Biochem. 267 (2000) 5342
18. Zhao, L.; Huang, W.; Liu, H.; Wang, L.; Zhong, W.; Xiao, J.; Hu, Y.; Li, S. J. Med. Chem., in press.
19. 2 incubator for 48 h prior to evaluation. The ganglia were observed and recorded under phase contrast with an Olympus CK2 inverted microscope. A total of 10-12 ganglia for each treatment were analyzed in each experimental run. Statistically significant differences between groups were determined by a one-way analysis of variance followed by a Student-Newman-Keuls post hoc analysis.
20. Tanaka K., Fujita N., and Ogawa N. Brain Res. 970 (2003) 250